Document:

Exhibit
10.2

 

SUPPORT
AGREEMENT

 

THIS
SUPPORT AGREEMENT (this “Agreement”) is entered into as of April 2, 2020, by and between 1315 Capital II,
L.P., a Delaware limited partnership (“1315 Capital”), and Interpace Biosciences, Inc., a Delaware corporation
(the “Company”).

 

BACKGROUND

 

WHEREAS,
pursuant to a Securities Purchase and Exchange Agreement, dated as of January 10, 2020, the Company issued, sold and delivered
to 1315 Capital, and 1315 Capital purchased and acquired from the Company, pursuant to the terms and subject to the conditions
set forth therein, an aggregate of 19,000 shares of the Company’s Series B Convertible Preferred Stock, par value $0.01
per share (the “Series B Shares”).

 

WHEREAS,
the Series B Shares have the designation, powers, preferences and rights, and the qualifications, limitations and restrictions,
as specified in the Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock
filed with the Secretary of State of the State of Delaware on January 14, 2020 (the “Certificate of Designation”).

 

WHEREAS,
the Company and 1315 Capital are parties to that certain Amended and Restated Investor Rights Agreement, entered into as of January
15, 2020 (the “Investor Rights Agreement”), by and among the Company, 1315 Capital and Ampersand 2018 Limited
Partnership, a Delaware limited partnership (“Ampersand”), which establishes certain terms and conditions concerning
the rights of and restrictions on 1315 Capital and Ampersand with respect to the ownership of the Series B Shares and other capital
stock of the Company.

 

WHEREAS,
the Company and 1315 Capital desire to enter into this Agreement in order to set forth their mutual understanding with respect
to certain consent and voting rights of 1315 Capital as set forth in the Certificate of Designation and Investor Rights Agreement.

 

NOW
THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt and sufficiency of which
is hereby acknowledged and intending to be legally bound, the parties hereby agree as follows:

 

1.
Shares Subject to this Agreement. 1315 Capital hereby agrees to vote all Series B Shares registered in its name or beneficially
owned by it and/or over which it exercises voting control as of the date of this Agreement and any other Series B Shares legally
or beneficially held or acquired by 1315 Capital after the date hereof or over which it exercises voting control (the “Shares”)
in accordance with the provisions of this Agreement.

 

2.
Agreement to Vote Shares. 1315 Capital hereby consents to, and agrees to vote (by proxy or otherwise) its Shares in favor
of, any Fundamental Action desired to be taken by the Company as determined by the Company’s Board of Directors. For purposes
of this Agreement, “Fundamental Action” shall mean any action proposed to be taken by the Company and set forth
in Section 4(d)(i), 4(d)(ii), 4(d)(v) 4(d)(vi), 4(d)(viii) or 4(d)(ix) of the Certificate of Designation or Section 8.5.1.1, 8.5.1.2,
8.5.1.5, 8.5.1.6, 8.5.1.8 or 8.5.1.9 of the Investor Rights Agreement. Except as set forth in this Section 2, 1315 Capital shall
retain all other rights, including the right to consent to any action other than a Fundamental Action, set forth in Section 4(d)
of the Certificate of Designation or Section 8.5 of the Investor Rights Agreement.

 

    	 

     

    

 

3.
No Ownership Interest. Nothing contained in this Agreement shall be deemed to vest in the Company any direct or indirect
ownership or incidence of ownership of or with respect to any Shares.

 

4.
Miscellaneous.

 

(a)
Notices. All notices, requests, and other communications hereunder shall be in writing and will be deemed to have been
duly given and received (a) when personally delivered, (b) when sent by facsimile or email upon confirmation of receipt, (c) one
business day after the day on which the same has been delivered prepaid to a nationally recognized courier service, or (d) five
business days after the deposit in the United States mail, registered or certified, return receipt requested, postage prepaid,
in each case addressed:

 

If
to the Company to:

 

Interpace
Biosciences, Inc.

Morris
Corporate Center 1, Building C

300
Interpace Parkway, Parsippany, NJ 07054

Attention:
Jack E. Stover, President and CEO

Email:
jstover@interpace.com

 

With
a copy to:

 

Pepper
Hamilton LLP

620
Eighth Avenue, 37th Floor

New
York Times Building

New
York, NY 10018

Attention:
Merrill M. Kraines, Esquire

Email:
krainesm@pepperlaw.com

 

If
to 1315 Capital to:

 

1315
Capital II, L.P.

2929
Walnut Street, Suite 1240

Philadelphia,
PA 19104

Attention:
Adele C. Oliva, Founding Partner

Email:
adele.oliva@1315capital.com

 

With
a copy to:

 

Morgan,
Lewis & Bockius LLP

1701
Market Street

Philadelphia,
PA 19103-2921

Attention:
Joanne R. Soslow, Esquire

Email:
joanne.soslow@morganlewis.com

 

Any
party hereto from time to time may change its address, facsimile number, or other information for the purpose of notices to that
party by giving notice specifying such change to the other parties hereto. 1315 Capital and the Company may each agree in writing
to accept notices and other communications to it hereunder by electronic communications pursuant to procedures reasonably approved
by it; provided that approval of such procedures may be limited to particular notices or communications.

 

    	 

     

    

 

(b)
Amendments; Waiver. This Agreement may be amended by the parties hereto, and the terms and conditions hereof may be waived,
only by an instrument in writing and signed by 1315 Capital and the Company. The failure of any party hereto to exercise any right,
power or remedy provided under this Agreement or otherwise available in respect of this Agreement at law or in equity, or to insist
upon compliance by any other party with its obligation under this Agreement, and any custom or practice of the parties at variance
with the terms of this Agreement, shall not constitute a waiver by such party of such party’s right to exercise any such
or other right, power or remedy or to demand such compliance.

 

(c)
Rules of Construction. The parties hereto hereby waive the application of any law, regulation, holding or rule of construction
providing that ambiguities in an agreement or other document will be construed against the party drafting such agreement or document.

 

(d)
Counterparts. This Agreement may be executed in one or more counterparts, all of which shall be considered one and the
same instrument and shall become effective when one or more counterparts have been signed by each of the parties and delivered
to the other parties hereto; it being understood that all parties need not sign the same counterpart.

 

(e)
Severability. In the event that any provision of this Agreement, or the application thereof, becomes or is declared by
a court of competent jurisdiction to be illegal, void or unenforceable, the remainder of this Agreement shall continue in full
force and effect and the application of such provision to other persons or circumstances shall be interpreted so as reasonably
to effect the intent of the parties hereto. The parties hereto further agree to use their commercially reasonable efforts to replace
such void or unenforceable provision of this Agreement with a valid and enforceable provision that shall achieve, to the extent
possible, the economic, business and other purposes of such void or unenforceable provision.

 

(f)
Governing Law; Consent to Jurisdiction. This Agreement, and the provisions, rights, obligations, and conditions set forth
herein, and the legal relations between the parties hereto, including all disputes and claims, whether arising in contract, tort,
or under statute, shall be governed by and construed in accordance with the laws of the State of Delaware without giving effect
to its conflict of law provisions.

 

(g)
Expenses. All costs and expenses incurred in connection with this Agreement and the transactions contemplated hereby shall
be paid by the party incurring the expenses.

 

(h)
WAIVER OF JURY TRIAL. EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES ALL RIGHT TO TRIAL BY JURY IN ANY ACTION, PROCEEDING
OR COUNTERCLAIM (WHETHER BASED ON CONTRACT, TORT, OR OTHERWISE) ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE ACTIONS OF
ANY PARTY HERETO IN NEGOTIATION, ADMINISTRATION, PERFORMANCE OR ENFORCEMENT HEREOF.

 

    	 

     

    

 

IN
WITNESS WHEREOF, the parties hereto have caused this SUPPORT AGREEMENT to be executed as of the date first written
above.

 

	 	INTERPACE
    BIOSCIENCES, INC.
	 	 	 
	 	By:	/s/
    Jack E. Stover
	 	Name:
    	Jack
    E. Stover
	 	Title:
    	President
    & CEO

 

    	 

     

    

 

IN
WITNESS WHEREOF, the parties hereto have caused this SUPPORT AGREEMENT to be executed as of the date first written
above.

 

	 	1315
    CAPITAL II, L.P.
	 	 
	 	By:	1315
    Capital Management II, LLC,
	 	 	its
    General Partner
	 	 	 
	 	By:	/s/
    Adele C. Oliva
	 	Name:
    	Adele
    C. Oliva
	 	Title:
    	Managing
    MemberExhibit
10.3

 

TERMINATION
AGREEMENT

 

This
Termination Agreement (this “Agreement”), is made and entered into on July 9, 2020, by and between Ampersand
2018 Limited Partnership, a Delaware limited partnership (“Ampersand”), and Interpace Biosciences, Inc., a
Delaware corporation (the “Company”). Ampersand and the Company are sometimes referred to individually as a
“Party” and collectively as the “Parties”.

 

RECITALS:

 

WHEREAS,
the Parties entered into that certain Support Agreement dated April 7, 2020 (the “Support Agreement”), pursuant
to which Ampersand agreed to vote any shares of the Company owned by it in favor of certain fundamental actions desired to be
taken by the Company as determined by the Company’s Board of Directors;

 

WHEREAS,
the Company is considering applying for a loan pursuant to the Paycheck Protection Program of 2020 administrated by the US Small
Business Administration (the “PPP Loan”); and

 

WHEREAS,
the Parties hereby wish to terminate the Support Agreement if (i) the PPP Loan is not applied for by the Company by June 30, 2020,
(ii) the Company’s application for the PPP Loan is not approved by a participating bank and/or the US Small Business Administration,
as applicable, by September 30, 2020 or (iii) the PPP Loan to the Company is not funded by September 30, 2020 (the occurrence
of any of (i), (ii) or (iii), the “Termination Event”).

 

NOW,
THEREFORE, in consideration of the mutual promises and covenants contained herein, the receipt and sufficiency of which is
hereby acknowledged, the Parties do hereby agree as follows:

 

1.Termination.
Upon the occurrence of a Termination Event, the Support Agreement shall automatically be terminated and of no further force and
effect, and neither Ampersand nor the Company shall have any further rights or obligations under the Support Agreement from and
after the date of such Termination Event.

 

2.
General.

 

a.
Each of the Parties represents to the other that the execution, delivery and performance of this Agreement has been authorized
by all requisite corporate action of such Party and that the persons signing this Agreement on behalf of such Party are duly authorized
to do so.

 

b.
This Agreement contains the entire understanding between the Parties hereto with respect to the termination of the Support Agreement
and there are no oral understandings or other agreements between the Parties with respect to the termination of the Support Agreement
that have not been incorporated herein.

 

c.
This Agreement shall be governed by and construed and enforced in accordance with the laws of the State of Delaware without regard
to conflicts of laws principles thereof or any other jurisdiction.

 

d.
This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which taken together shall
constitute one and the same agreement. Signatures via facsimile or email shall be treated as original signatures in all respects.

 

e.
This Agreement is intended to be binding upon and inure to the benefit of each of the Parties and their respective employees,
officers, directors, members, shareholders, agents, representatives, successors and assigns.

 

[Signature
Page Follows]

 

    	 

     

    

 

IN
WITNESS WHEREOF, the parties hereto have executed this Termination Agreement on the date and year first indicated above.

 

	 	Ampersand
    2018 Limited Partnership
	 	 	 
	 	By:
    	AMP-18
    Management Company Limited Partnership, its General Partner
	 	 	 
	 	By:
    	AMP-18
    MC LLC, its General Partner
	 	 	 
	 	Signature:
    	/s/
    Herbert H. Hooper
	 	Name:
    	Herbert
    H. Hooper
	 	Title:
    	Managing
    Member
	 	 	 
	 	Interpace
    Biosciences, Inc.
	 	 	 
	 	Signature:	/s/
    Jack E. Stover
	 	Name:
    	Jack
    E. Stover
	 	Title:
    	President
    & CEO

 

Signature
Page to Termination Agreement

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00315-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00315-of-00352.parquet"}]]